SB
Scott L Burrows (Chief Financial Officer) filed 8 Form 4 reports in the trailing twelve months (0 purchases, 8 sales), most often in Spyre Therapeutics, Inc. (SYRE). The largest single filing was $2.2M of SYRE (24,632 sh across 3 lots, as filed), executed Sep 1. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
8
0 buys · 8 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.8M
shares × price, as filed
Last traded
Oct 1
Filed Oct 2
Median ADV $134.1M across their filed names
Open performance→Volume by month
Buys $0
Sells $9.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
8 filings
Sector per market data · by filing · past 12 months
Most traded names
SYRERecent filings
SYRESALE
Spyre Therapeutics, Inc.
View filing →
$2.2M24,171 sh across 4 lots
Exec Sep 30
Filed Oct 2 · 9:29 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $2.2M
24,632 sh across 3 lots
Exec Sep 1
Filed Sep 3 · 9:33 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $707K
7,400 sh across 2 lots
Exec Aug 3
Filed Aug 5 · 9:32 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $658K
7,500 sh across 2 lots
Exec Jul 1
Filed Jul 2 · 9:33 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $1.3M
15,000 sh across 2 lots
Exec Jun 25
Filed Jun 26 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $533K
7,500 sh across 3 lots
Exec Jun 1
Filed Jun 3 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $892K
12,500 sh × $71.37
Exec May 1
Filed May 1 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $305K
6,200 sh × $49.21
Exec Apr 1
Filed Apr 3 · 5:30 PM ET More filings →